Happy Valley

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Researchers are evaluating the effectiveness of Rina-S (GEN1184) compared to standard chemotherapy treatments chosen by physicians for women with recurrent or progressive endometrial cancer after prior therapy. This Phase 3, global, open-label study involves about 660 participants who have previously been treated with platinum-based chemotherapy and PD(L)-1 inhibitors. The study aims to assess how well these treatments control cancer progression and improve survival over approximately three years. Participants will be randomly assigned to receive either Rina-S through intravenous infusion or one of two chemotherapy options: paclitaxel given by IV infusion or doxorubicin administered as an IV bolus injection or infusion. Each participant's treatment will be decided before randomization if assigned to the investigator's choice arm. Treatment duration varies but is expected to average between four to six months. Throughout the study, participants will visit study sites for treatment and monitoring. Researchers will evaluate progression-free survival and overall survival up to about three years, using blinded independent central review according to established cancer response criteria. Safety and treatment effects will be carefully monitored during this time. No placebo treatments will be given, and all participants will receive an active drug.